NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

BSX

105.3

+0.4%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

BSX

105.3

+0.4%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

BSX

105.3

+0.4%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

BSX

105.3

+0.4%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

BSX

105.3

+0.4%↑

Search

Johnson and Johnson

Închisă

SectorSănătate

167.25 1.51

Rezumat

Modificarea prețului

24h

Curent

Minim

164.78

Maxim

167.58

Indicatori cheie

By Trading Economics

Venit

-5.5B

5.5B

Vânzări

1.9B

24B

P/E

Medie Sector

17.797

40.048

EPS

2.77

Randament dividend

2.98

Marjă de profit

23.321

Angajați

138,100

EBITDA

-9.1B

6.5B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+6.76% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

2.98%

2.45%

Următoarele câștiguri

14 oct. 2025

Data viitoare de dividende

9 sept. 2025

Următoarea dată ex-dividende

26 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

23B

400B

Deschiderea anterioară

165.74

Închiderea anterioară

167.25

Sentimentul știrilor

By Acuity

36%

64%

98 / 375 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Johnson and Johnson Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 iul. 2025, 16:47 UTC

Câștiguri

J&J Raises Full-Year Outlook After Beating 2Q Expectations -- Update

16 iul. 2025, 18:08 UTC

Market Talk
Câștiguri

J&J's Orthopedic Decline Likely Hinges on Company-Specific Challenges -- Market Talk

16 iul. 2025, 17:27 UTC

Market Talk
Câștiguri

J&J Expects Medical Devices Sales Boost from Cardiovascular -- Market Talk

16 iul. 2025, 17:17 UTC

Market Talk
Câștiguri

J&J Sees Growth Across Portfolio Offsetting Loss of Stelara -- Market Talk

16 iul. 2025, 16:34 UTC

Market Talk
Câștiguri

J&J Sees Lower Tariff Risk for the Year -- Market Talk

16 iul. 2025, 13:27 UTC

Câștiguri

Johnson & Johnson Beats Earnings Estimates. CFO Says It Can Do Any Deal It Wants. -- Barrons.com

16 iul. 2025, 10:32 UTC

Câștiguri

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants. -- Barrons.com

16 iul. 2025, 10:22 UTC

Câștiguri

Correct: Johnson & Johnson 2Q International Sales $10.2B >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants. -- Barrons.com

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.63-$10.73 Vs Prior Outlook $10.50-$10.70 >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson Raises 2025 View To Sales $93.2B-$93.6B Vs Prior Outlook $91B-$91.8B >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson Raises 2025 View To Adj EPS $10.80-Adj EPS $10.90 Vs Prior Outlook $10.50-$10.70 >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson: Increasing 2025 Operational Sales Growth to Be in Range of 4.5%-5% Vs Prior Range 3.3%-4.3% >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson Now Sees 2025 Operational Sales of $92.7B-$93.1B Vs Prior Outlook $91.6B-$92.4B>JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson: Our Portfolio and Pipeline Position Us for Elevated Growth in Second Half of Year >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson Now Sees 2025 Adjusted Operational Sales Growth of 3.2%-3.7% Vs Prior Outlook 2%-3% >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson: 2Q MedTech Business Delivered Operational Sales Growth of 6.1%, Driven Primarily by Strength in Electrophysiology Products and Abiomed, Wound Closure Pdts and Improved Performance in Surgical Vision >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson 2Q Worldwide MedTech Sales $8.54B >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson: 2Q Innovative Medicine Operational Sales Growth Driven by Darzalex, Carvykti, Rybrevant, Lazcluze, Tremfya and Spravato >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson: 2Q Innovative Medicine Operational Sales Grew 3.8% With 13 Brands Growing Double Digits >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson 2Q International Sales $23.74B >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson 2Q Worldwide Innovative Medicine Sales $15.2B >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson 2Q U.S. Sales $13.54B >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson 2Q Sales $23.74B >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson 2Q EPS $2.29 >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson 2Q Adj EPS $2.77 >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson 2Q Orthopaedics Sales $2.3B >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson 2Q Orthopaedics Sales $2.31B >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson 2Q International Sales $10.2B >JNJ

16 iul. 2025, 10:20 UTC

Câștiguri

Johnson & Johnson 2Q Worldwide Innovative Medicine Sales $15.2B >JNJ

Comparație

Modificare preț

Johnson and Johnson Așteptări

Obiectiv de preț

By TipRanks

6.76% sus

Prognoză pe 12 luni

Medie 175.88 USD  6.76%

Maxim 190 USD

Minim 160 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruJohnson and Johnson - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

18 ratings

8

Cumpărare

10

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

154.93 / 155.895Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

98 / 375 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.